Voyager Therapeutics (VYGR)
Develops CNS gene therapies and antibodies around TRACER delivery and tau biology.
$2.96
vs last close−0.18 (−5.65%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 57.02% | 35.14M shares | |
|---|---|---|---|
| 144 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.21% | 1.36M shares | |
| 8 holders · as of May 18, 2026 | |||
| Strategic holders | 5.42% | 3.34M shares | |
| 1 holder · as of Jan 26, 2026 | |||
| Other | ≈ 35.35% | 21.78M shares | |
| remainder | |||
61.62M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
144 holders · 35.14M shares · 22 new positions · 80 increased · 34 reduced · 18 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.17M | 8.39% | −396.3K | Aug 7, 2026 |
| Millennium Management LLC | 4.44M | 7.21% | +1.01M | Aug 14, 2026 |
| Armistice Capital, LLC | 3.44M | 5.58% | −64.0K | Aug 14, 2026 |
| Vestal Point Capital, LP | 2.63M | 4.26% | −377.9K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.35M | 3.81% | +62.4K | Aug 13, 2026 |
| Geode Capital Management, LLC | 1.33M | 2.16% | +280.5K | Aug 12, 2026 |
| Opaleye Management Inc. | 1.19M | 1.92% | +35.0K | Aug 14, 2026 |
| State Street Corp | 1.08M | 1.75% | +128.2K | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.65% | 4.80M | 13G | Aug 14, 2025 |
| BlackRock, Inc. | 6.40% | 3.53M | 13G | Apr 24, 2025 |
| Integrated Core Strategies (US) LLC | 6.00% | 3.34M | 13G | Jan 26, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Apr 2, 2026 | Alfred Sandrockdirector, officer: President and CEO | Sale | 11,511 | $3.87 | 472,549 |
| Feb 24, 2026 | Todd Alfred Carterofficer: Chief Scientific Officer | Sale | 4,174 | $3.76 | 145,718 |
| Feb 24, 2026 | Nathan D. Jorgensenofficer: Chief Financial Officer | Sale | 4,668 | $3.77 | 151,416 |
| Feb 24, 2026 | Alfred Sandrockdirector, officer: President and CEO | Sale | 14,197 | $3.79 | 484,060 |
| Feb 24, 2026 | Robin Swartzofficer: COO & CBO | Sale | 6,458 | $3.77 | 199,738 |
| Feb 18, 2026 | Alfred Sandrockdirector, officer: President and CEO | Sale | 11,732 | $3.41 | 498,257 |
| Feb 18, 2026 | Todd Alfred Carterofficer: Chief Scientific Officer | Sale | 3,301 | $3.44 | 149,892 |
| Feb 18, 2026 | Robin Swartzofficer: COO & CBO | Sale | 3,882 | $3.44 | 206,196 |
| Feb 10, 2026 | Todd Alfred Carterofficer: Chief Scientific Officer | Sale | 3,525 | $3.85 | 153,193 |
| Feb 10, 2026 | Alfred Sandrockdirector, officer: President and CEO | Sale | 12,192 | $3.78 | 509,989 |
House and Senate disclosures
Not reported.